GRFS - Grifols: A Market Setback Turns Into Buying Opportunity
2025-04-23 11:10:00 ET
Summary
- Grifols, a Spanish multinational specializing in plasma-derived therapies, is undervalued due to historical mismanagement but holds a strong market position with significant competitive advantages.
- New management has implemented an operational improvement plan, showing positive results in 2024, including record revenues, improved EBITDA margins, and increased free cash flow.
- Key risks include potential U.S. immigration policies affecting plasma supply and the emergence of recombinant protein substitutes, which could erode revenue by 2028.
- The business is poised for growth with a strategic plan targeting revenue growth, improved margins, and significant free cash flow generation, making it an attractive investment opportunity.
The following segment was excerpted from White Falcon Capital's Q1 2025 Partner's Letter.
Grifols S.A.
Founded in 1909, Grifols ( GRFS ) is a family-owned Spanish multinational specializing in plasma-derived therapies. Operating in the arcane hemoderivatives industry, Grifols is a market leader and holds ~70% market share in the U.S. along with its two largest competitors: CSL ( OTCQX:CSLLY ) and Takeda ( TAK ).
The business generates ~80% of its revenue from its Biopharma segment which procures, researches, manufactures, and sells therapeutic products derived from plasma. The proteins in the plasma can be used to treat a variety of autoimmune and neurological diseases. Over the years, Grifols has built substantial infrastructure which is difficult to replicate:
- Grifols operates 390 plasma donation centers, where they compensate donors for plasma, which constitutes ~35% of raw material costs. This raw material is frozen for two months before being transported to a fractionation site.
- At their manufacturing facility - a fractionation plant - the plasma is isolated into the individual proteins. Here, they also conduct a variety of tests to meet strict regulations.
- The proteins are then sent to one of their facilities (U.S., Spain, or Ireland), for final packaging and delivery to their customers which can be hospitals, pharmacies or physician offices.